Due to our extensive coverage of the Keystone Symposia meeting, we will not include any spotlights this week. We will report on the AACR Annual Meeting next week, so our regular digest will be back on April 24th.
There are no spotlights this week
SpotlightDue to our extensive coverage of the Keystone Symposia meeting, we will not include any spotlights this week. We will report on the AACR Annual Meeting next week, so our regular digest will be back on April 24th.
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy Spotlight
(1) Revach OY (2) Cicerchia AM (3) Shorer O (4) Petrova B (5) Anderson S (6) Park J (7) Chen L (8) Mehta A (9) Wright SJ (10) McNamee N (11) Tal-Mason A (12) Cattaneo G (13) Tiwari P (14) Xie H (15) Sweere JM (16) Cheng LC (17) Sigal N (18) Enrico E (19) Miljkovic M (20) Evans SA (21) Nguyen N (22) Whidden ME (23) Srinivasan R (24) Spitzer MH (25) Sun Y (26) Sharova T (27) Lawless AR (28) Michaud WA (29) Rasmussen MQ (30) Fang J (31) Palin CA (32) Chen F (33) Wang X (34) Ferrone CR (35) Lawrence DP (36) Sullivan RJ (37) Liu D (38) Sachdeva UM (39) Sen DR (40) Flaherty KT (41) Manguso RT (42) Bod L (43) Kellis M (44) Boland GM (45) Yizhak K (46) Yang J (47) Kanarek N (48) Sade-Feldman M (49) Hacohen N (50) Jenkins RW
Revach et al. showed that in ICB-treated patients with melanoma or NSCLC, CD8+ TIL expression of CD38, an ecto-enzyme involved in NAD+ catabolism, increased in parallel with co-inhibitory receptor and inversely with Tcf7 expression, and predicted ICB resistance. Cd38 was upregulated in exhausted CD8+ TILs of ICB-treated tumor-bearing mice, and Cd38 deletion reduced chronic stimulation-induced T cell dysfunction. CD38 blockade overcame ICB resistance in mouse- and patient-derived organotypic tumor spheroids. CD38 blockade or deletion reversed metabolic defects in exhausted T cells to allow Tcf7 expression, T cell function, and ICB response.
Contributed by Paula Hochman
(1) Revach OY (2) Cicerchia AM (3) Shorer O (4) Petrova B (5) Anderson S (6) Park J (7) Chen L (8) Mehta A (9) Wright SJ (10) McNamee N (11) Tal-Mason A (12) Cattaneo G (13) Tiwari P (14) Xie H (15) Sweere JM (16) Cheng LC (17) Sigal N (18) Enrico E (19) Miljkovic M (20) Evans SA (21) Nguyen N (22) Whidden ME (23) Srinivasan R (24) Spitzer MH (25) Sun Y (26) Sharova T (27) Lawless AR (28) Michaud WA (29) Rasmussen MQ (30) Fang J (31) Palin CA (32) Chen F (33) Wang X (34) Ferrone CR (35) Lawrence DP (36) Sullivan RJ (37) Liu D (38) Sachdeva UM (39) Sen DR (40) Flaherty KT (41) Manguso RT (42) Bod L (43) Kellis M (44) Boland GM (45) Yizhak K (46) Yang J (47) Kanarek N (48) Sade-Feldman M (49) Hacohen N (50) Jenkins RW
Revach et al. showed that in ICB-treated patients with melanoma or NSCLC, CD8+ TIL expression of CD38, an ecto-enzyme involved in NAD+ catabolism, increased in parallel with co-inhibitory receptor and inversely with Tcf7 expression, and predicted ICB resistance. Cd38 was upregulated in exhausted CD8+ TILs of ICB-treated tumor-bearing mice, and Cd38 deletion reduced chronic stimulation-induced T cell dysfunction. CD38 blockade overcame ICB resistance in mouse- and patient-derived organotypic tumor spheroids. CD38 blockade or deletion reversed metabolic defects in exhausted T cells to allow Tcf7 expression, T cell function, and ICB response.
Contributed by Paula Hochman
ABSTRACT: A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma(1,2). T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance(3). Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD(+)) catabolism, is highly expressed in exhausted CD8(+) T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38(hi)CD8(+) T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics. Genetic and pharmacological blockade of CD38 in murine and patient-derived organotypic tumour models (MDOTS/PDOTS) enhanced tumour immunity and overcame ICB resistance. Mechanistically, disrupting CD38 activity in T cells restored cellular NAD(+) pools, improved mitochondrial function, increased proliferation, augmented effector function, and restored ICB sensitivity. Taken together, these data demonstrate a role for the CD38-NAD(+) axis in promoting T cell exhaustion and ICB resistance and establish the efficacy of CD38 directed therapeutic strategies to overcome ICB resistance using clinically relevant, patient-derived 3D tumour models.
Author Info: (1) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, M
Author Info: (1) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (2) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. (3) Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. (4) Harvard Medical School, Boston, MA, USA. Department of Pathology, Boston Children's Hospital, Boston, MA, USA. (5) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (6) Broad Institute of MIT and Harvard, Cambridge, MA, USA. (7) Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA, USA. (8) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (9) Broad Institute of MIT and Harvard, Cambridge, MA, USA. (10) Harvard Medical School, Boston, MA, USA. Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA. (11) Harvard Medical School, Boston, MA, USA. Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA. (12) Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (13) Broad Institute of MIT and Harvard, Cambridge, MA, USA. (14) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (15) Teiko Bio, Salt Lake City, UT, USA. (16) Teiko Bio, Salt Lake City, UT, USA. (17) Teiko Bio, Salt Lake City, UT, USA. (18) Teiko Bio, Salt Lake City, UT, USA. (19) Teiko Bio, Salt Lake City, UT, USA. (20) Teiko Bio, Salt Lake City, UT, USA. (21) Teiko Bio, Salt Lake City, UT, USA. (22) Teiko Bio, Salt Lake City, UT, USA. (23) Teiko Bio, Salt Lake City, UT, USA. (24) Teiko Bio, Salt Lake City, UT, USA. Department of Otolaryngology-Head and Neck Cancer, University of California, San Francisco, San Francisco, CA, USA. Department of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, USA. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Chan Zuckerberg Biohub, San Francisco, CA 94158; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (25) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. (26) Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (27) Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (28) Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (29) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (30) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (31) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. (32) Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (33) Harvard Medical School, Boston, MA, USA. Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (34) Harvard Medical School, Boston, MA, USA. Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. Department of Surgery, Cedars-Sinai Medical Center Los Angeles, CA, USA. (35) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. (36) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. (37) Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (38) Harvard Medical School, Boston, MA, USA. Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA. (39) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (40) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. (41) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (42) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (43) Department of Pathology, Boston Children's Hospital, Boston, MA, USA. (44) Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. (45) Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. (46) Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA, USA. (47) Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Pathology, Boston Children's Hospital, Boston, MA, USA. (48) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (49) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (50) Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Citation: bioRxiv 2024 Feb 17 Epub02/17/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38405985
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses Spotlight
(1) Kelly RJ (2) Landon BV (3) Zaidi AH (4) Singh D (5) Canzoniero JV (6) Balan A (7) Hales RK (8) Voong KR (9) Battafarano RJ (10) Jobe BA (11) Yang SC (12) Broderick S (13) Ha J (14) Marrone KA (15) Pereira G (16) Rao N (17) Borole A (18) Karaindrou K (19) Belcaid Z (20) White JR (21) Ke S (22) Amjad AI (23) Weksler B (24) Shin EJ (25) Thompson E (26) Smith KN (27) Pardoll DM (28) Hu C (29) Feliciano JL (30) Anagnostou V (31) Lam VK
Kelly, Landon, and Zaidi et al. reported the safety, feasibility, and efficacy of neoadjuvant nivolumab (Arm A) or nivolumab plus relatlimab (Arm B) combined with chemoradiotherapy in patients with resectable stage II/stage III gastroesophageal cancer. The primary endpoint of safety for Arm A was met, but required an amendment to mitigate toxicity in Arm B. The pCR rate was 40% for Arm A and 21.4% for Arm B, and the 2-year OS rates were 82.6% in Arm A and 93.8% in Arm B. Circulating tumor DNA (ctDNA) analysis was predictive of tumor regression, RFS, and OS, outperforming pCR and MPR. Neoantigen-specific T cell responses paralleled ctDNA kinetics.
Contributed by Shishir Pant
(1) Kelly RJ (2) Landon BV (3) Zaidi AH (4) Singh D (5) Canzoniero JV (6) Balan A (7) Hales RK (8) Voong KR (9) Battafarano RJ (10) Jobe BA (11) Yang SC (12) Broderick S (13) Ha J (14) Marrone KA (15) Pereira G (16) Rao N (17) Borole A (18) Karaindrou K (19) Belcaid Z (20) White JR (21) Ke S (22) Amjad AI (23) Weksler B (24) Shin EJ (25) Thompson E (26) Smith KN (27) Pardoll DM (28) Hu C (29) Feliciano JL (30) Anagnostou V (31) Lam VK
Kelly, Landon, and Zaidi et al. reported the safety, feasibility, and efficacy of neoadjuvant nivolumab (Arm A) or nivolumab plus relatlimab (Arm B) combined with chemoradiotherapy in patients with resectable stage II/stage III gastroesophageal cancer. The primary endpoint of safety for Arm A was met, but required an amendment to mitigate toxicity in Arm B. The pCR rate was 40% for Arm A and 21.4% for Arm B, and the 2-year OS rates were 82.6% in Arm A and 93.8% in Arm B. Circulating tumor DNA (ctDNA) analysis was predictive of tumor regression, RFS, and OS, outperforming pCR and MPR. Neoantigen-specific T cell responses paralleled ctDNA kinetics.
Contributed by Shishir Pant
ABSTRACT: Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy responses for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab-relatlimab (Arm B, n = 16) in combination with chemoradiotherapy in 32 patients with resectable stage II/stage III gastroesophageal cancer together with an in-depth evaluation of pathological, molecular and functional immune responses. Primary endpoint was safety; the secondary endpoint was feasibility; exploratory endpoints included pathological complete (pCR) and major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). The study met its primary safety endpoint in Arm A, although Arm B required modification to mitigate toxicity. pCR and MPR rates were 40% and 53.5% for Arm A and 21.4% and 57.1% for Arm B. Most common adverse events were fatigue, nausea, thrombocytopenia and dermatitis. Overall, 2-year RFS and OS rates were 72.5% and 82.6%, respectively. Higher baseline programmed cell death ligand 1 (PD-L1) and LAG-3 expression were associated with deeper pathological responses. Exploratory analyses of circulating tumor DNA (ctDNA) showed that patients with undetectable ctDNA post-ICI induction, preoperatively and postoperatively had a significantly longer RFS and OS; ctDNA clearance was reflective of neoantigen-specific T cell responses. Our findings provide insights into the safety profile of combined PD-1 and LAG-3 blockade in gastroesophageal cancer and highlight the potential of ctDNA analysis to dynamically assess systemic tumor burden during neoadjuvant ICI that may open a therapeutic window for future intervention. ClinicalTrials.gov registration: NCT03044613 .
Author Info: (1) The Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA. ronan.kelly@bswhealth.org. (2) The Sidney Kimmel Comprehensive Cancer Center, Johns Hop
Author Info: (1) The Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA. ronan.kelly@bswhealth.org. (2) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (3) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (4) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (5) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (6) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (7) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (8) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (9) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (10) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (11) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (12) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (13) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (14) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (15) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (16) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (17) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (18) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (19) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (20) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (21) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. (22) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (23) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (24) Department of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (25) Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (26) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (27) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (28) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. (29) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (30) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. (31) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vklam@jhmi.edu.
Citation: Nat Med 2024 Mar 19 Epub03/19/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38504015
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3_anti-GD2 bispecific antibody armed T cells
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2)
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (3) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (4) Children's Hospital of Michigan, Detroit, Michigan, USA. (5) Children's Hospital of Michigan, Detroit, Michigan, USA. (6) Children's Hospital of Michigan, Detroit, Michigan, USA. (7) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (8) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (9) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (10) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (11) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (12) Wistar Institute, Philadelphia, Pennsylvania, USA. (13) Karmanos Cancer Institute, Detroit, Michigan, USA. (14) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (15) University of Virginia Cancer Center, Charlottesville, Virginia, USA yankelevic@gmail.com LGL4F@uvahealth.org.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519053
CD155 as an emerging target in tumor immunotherapy
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of He
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (2) Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, China. (3) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (4) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (5) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: yichaozheng@zzu.edu.cn. (6) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: liuhuimin@zzu.edu.cn.
Citation: Int Immunopharmacol 2024 Mar 21 131:111896 Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518596
The role of extracellular vesicle immune checkpoints in cancer
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laborat
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing Jiangsu, China. (3) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (4) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Citation: Clin Exp Immunol 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518192
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum vo
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (3) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (4) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (5) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (6) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (7) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (8) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (9) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (10) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (11) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (12) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (13) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (14) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (15) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (16) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (17) Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (18) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (19) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (20) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Department of Hematology, UMC Utrecht, Utrecht, The Netherlands. (21) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (22) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (23) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (24) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (25) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (26) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands S.Nierkens-2@prinsesmaximacentrum.nl. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519054
Engineered extracellular vesicles enable high-efficient delivery of intracellular therapeutic proteins
(1) Ma D (2) Xie A (3) Lv J (4) Min X (5) Zhang X (6) Zhou Q (7) Gao D (8) Wang E (9) Gao L (10) Cheng L (11) Liu S
(1) Ma D (2) Xie A (3) Lv J (4) Min X (5) Zhang X (6) Zhou Q (7) Gao D (8) Wang E (9) Gao L (10) Cheng L (11) Liu S
Author Info: (1) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blo
Author Info: (1) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (2) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. (3) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (4) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (5) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (6) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (7) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (8) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. (9) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. (10) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. (11) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Citation: Protein Cell 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518087
Tags:
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United State
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United States. (4) University of Pittsburgh, Pittsburgh, PA, United States. (5) University of Pittsburgh, Pittsburgh, PA, United States.
Citation: Cancer Immunol Res 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38517470
Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells
(1) Dan Y (2) Ma J (3) Long Y (4) Jiang Y (5) Fang L (6) Bai J
(1) Dan Y (2) Ma J (3) Long Y (4) Jiang Y (5) Fang L (6) Bai J
Author Info: (1) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laborato
Author Info: (1) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (2) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (3) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (4) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (5) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; National Engineering Research Center of Ultrasound Medicine, Chongqing 401121, China. Electronic address: lqfang06@163.com. (6) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. Electronic address: sajinbai@cqmu.edu.cn.
Citation: Mol Immunol 2024 Mar 20 169:78-85 Epub03/20/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38513590